Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CA9 | Q16790 | 1/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | GPR3 | P46089 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.40 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.40 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.40 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.40 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PRNP | P04156 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29508386 | 1.00 | PDPK1 (0.55) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Ammonia Solution, Strong SCHEMBL4824906 | 0.98 | PDPK1 (0.53) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| SCHEMBL10427747 | 0.98 | PDPK1 (0.53) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4766699 | 0.98 | PDPK1 (0.53) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Formic Acid SCHEMBL10727380 | 0.90 | PDPK1 (0.50) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Formic Acid SCHEMBL10738924 | 0.88 | PDPK1 (0.49) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Acetic Acid SCHEMBL10727228 | 0.88 | SMN1; SMN2 (0.49) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Acetic Acid SCHEMBL10742452 | 0.87 | SMN1; SMN2 (0.47) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL29627985 | 0.84 | PARP1 (0.45) | PDPK1CA12PARP1ALOX15SMN1; SMN2 | |
| Water SCHEMBL10734174 | 0.82 | PDPK1 (0.40) | PDPK1CA12PARP1ALOX15SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4370515-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-05-22 | — | — | EP | claimed |
| US-20230044248-A1 | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2023-02-09 | — | — | US | claimed |
| WO-2023287896-A1 | TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2023-01-19 | — | — | WO | claimed |
| EP-4051279-A1 | COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | Ares Trading S.A. (CH) | 2022-09-07 | — | — | EP | claimed |
| EP-3919076-A1 | SYNTHETIC OLIGOSACCHARIDE VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE WITH MICROPARTICLE ADJUVANT FORMULATIONS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2021-12-08 | — | — | EP | claimed |
| US-20210353614-A1 | COMPOUNDS AND USES THEREOF TO TREAT TUMORS IN A SUBJECT | MERCK PATENT GMBH (DE) | 2021-11-18 | — | — | US | claimed |
| EP-3849615-A1 | COMPOSITIONS FOR THE TREATMENT OF DISEASE WITH IMMUNE STIMULATORY CONJUGATES | Silverback Therapeutics, Inc. (US) | 2021-07-21 | — | — | EP | claimed |
| WO-2021084124-A1 | COMBINED INHIBITION OF PD-1, TGFβ AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | ARES TRADING S.A. (CH) | 2021-05-06 | — | — | WO | claimed |
| EP-3765019-A1 | COMPOUNDS AND USES THEREOF TO TREAT TUMORS IN A SUBJECT | Merck Patent GmbH (DE) | 2021-01-20 | — | — | EP | claimed |
| US-10722591-B2 | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof | DYNAVAX TECHNOLOGIES CORPORATION (US) | 2020-07-28 | — | — | US | claimed |
| WO-2004011462-A1 | PREPARATION OF 1H-IMIDAZO [4,5-C] QUINOLIN-4-AMINES VIA NOVEL 1H-IMIDAZO [4,5-C] QUINOLIN-4-CYANO AND 1H-IMIDAZO [4,5-C] QUINOLIN-4-CARBOXAMIDE INTERMEDIATES | BIOGAL GYOGYSZERGYAR RT. (HU) | 2004-02-05 | — | — | WO | claimed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | claimed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | claimed |
| EP-0575549-B1 | PROCESS FOR IMIDAZO [4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING & MFG (US) | 1996-09-11 | — | — | EP | claimed |
| EP-0681570-A1 | PROCESS FOR PREPARING QUINOLINE AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-11-15 | — | — | EP | claimed |
| US-5395937-A | Process for preparing quinoline amines | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-03-07 | — | — | US | claimed |
| WO-1994017043-A1 | PROCESS FOR PREPARING QUINOLINE AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-08-04 | — | — | WO | claimed |
| EP-0575549-A1 | PROCESS FOR IMIDAZO 4,5-c]QUINOLIN-4-AMINES. | MINNESOTA MINING & MFG (US) | 1993-12-29 | — | — | EP | claimed |
| US-5175296-A | Reacting 1H-imidazolo(4,5-c)quinolin-5N-oxide with organic isocyanate; hydrolysis | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-12-29 | — | — | US | claimed |
| WO-1992015581-A1 | PROCESS FOR IMIDAZO[4,5-c]QUINOLIN-4-AMINES | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1992-09-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10722591-B2 | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof | TLR7, TLR8, TLR9 | PDPK1 1907/4885CA12 2101/4885PARP1 584/4885 |
| US-20210353614-A1 | COMPOUNDS AND USES THEREOF TO TREAT TUMORS IN A SUBJECT | CD274, PDCD1, PDCD1LG2 | PDPK1 152/4885CA12 213/4885PARP1 1076/4885 |
| US-20230044248-A1 | COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER | ATM, PDCD1, CD274 | PDPK1 50/4885CA12 4527/4885PARP1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.